文献速递自身炎症与 IgG4 相关病

VEXAS综合征靶向治疗的疗效与安全性:FRENVEX回顾性研究

Efficacy and safety of targeted therapies in VEXAS syndrome: retrospective study from the FRENVEX.
PubMed 文献 · Ann Rheum Dis · 2024-09-30

本研究基于FRENVEX多中心回顾性队列,纳入110例经基因确诊并至少接受一种靶向治疗的VEXAS综合征患者,共评估194次靶向治疗。3个月时JAK抑制剂总体缓解率24%、IL-6抑制剂32%、抗IL-1为9%、TNFα阻断剂及其他为0%;JAK抑制剂的无停药生存显著长于其他靶向治疗。作者认为JAK抑制剂与IL-6抑制剂有获益,其他疗法疗效较低,结论需前瞻性试验确认。

要点

  • 3个月总体缓解率:JAK抑制剂24%、IL-6抑制剂32%、抗IL-1为9%、TNFα阻断剂及其他为0%。
  • 6个月总体缓解率:JAK抑制剂30%、IL-6抑制剂26%。
  • JAK抑制剂的无停药生存显著长于其他靶向治疗。

核心结论

  • 作者认为JAK抑制剂和IL-6抑制剂对VEXAS综合征有获益,其他疗法疗效较低;这些结果需在前瞻性试验中确认。

研究设计与样本

  • FRENVEX多中心回顾性研究,纳入110例经基因确诊的VEXAS综合征患者,这些患者至少接受过一种靶向治疗,共194次靶向治疗。
  • 完全缓解定义为临床缓解、C反应蛋白≤10 mg/L且泼尼松等效剂量≤10 mg/日;部分缓解定义为临床缓解且C反应蛋白水平和糖皮质激素剂量均下降50%。

主要发现

  • 110例患者中位年龄71(68-79)岁;194次靶向治疗中JAK抑制剂78次(40%)、IL-6抑制剂51次(26%)、IL-1抑制剂33次(17%)、TNFα阻断剂20次(10%)、其他靶向治疗12次(6%)。
  • 3个月时总体缓解(完全缓解与部分缓解)率:JAK抑制剂24%、IL-6抑制剂32%、抗IL-1为9%、TNFα阻断剂或其他靶向治疗为0%。
  • 6个月时总体缓解率:JAK抑制剂30%、IL-6抑制剂26%。
  • JAK抑制剂的无停药生存显著长于其他靶向治疗。
  • 停药原因中,JAK抑制剂组原发性失败、继发性失败、严重不良事件、死亡分别为43%、14%、19%、19%;IL-6抑制剂组分别为46%、11%、31%、9%。

关键数值与推荐

  • 完全缓解:临床缓解、C反应蛋白≤10 mg/L且泼尼松等效剂量≤10 mg/日。
  • 部分缓解:临床缓解且C反应蛋白水平和糖皮质激素剂量均下降50%。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文结论指出这些结果需在前瞻性试验中确认。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: Vacuoles, E1 enzyme, X-linked, autoinflammatory and somatic (VEXAS) syndrome is an adult-onset autoinflammatory disease associated with somatic ubiquitin-like modifier-activating enzyme 1 (UBA1) mutations. We aimed to evaluate the efficacy and safety of targeted therapies. METHODS: Multicentre retrospective study including patients with genetically proven VEXAS syndrome who had received at least one targeted therapy. Complete response (CR) was defined by a clinical remission, C-reactive protein (CRP) ≤10 mg/L and a ≤10 mg/day of prednisone-equivalent therapy, and partial response (PR) was defined by a clinical remission and a 50% reduction in CRP levels and glucocorticoid dose. RESULTS: 110 patients (median age 71 (68-79) years) who received 194 targeted therapies were included: 78 (40%) received Janus kinase (JAK) inhibitors (JAKi), 51 (26%) interleukin (IL)-6 inhibitors, 33 (17%) IL-1 inhibitors, 20 (10%) tumour necrosis factor (TNFα) blockers and 12 (6%) other targeted therapies. At 3 months, the overall response (CR and PR) rate was 24% with JAKi, 32% with IL-6 inhibitors, 9% with anti-IL-1 and 0% with TNFα blockers or other targeted therapies. At 6 months, the overall response rate was 30% with JAKi and 26% with IL-6 inhibitors. Survival without treatment discontinuation was significantly longer with JAKi than with the other targeted therapies. Among patients who discontinued treatment, causes were primary failure, secondary failure, serious adverse event or death in 43%, 14%, 19% and 19%, respectively, with JAKi and 46%, 11%, 31% and 9%, respectively, with IL-6 inhibitors. CONCLUSIONS: This study shows the benefit of JAKi and IL-6 inhibitors, whereas other therapies have lower efficacy. These results need to be confirmed in prospective trials.

来源:Ann Rheum Dis,查看原文。版权归原作者所有。

引用

  1. Hadjadj J, Nguyen Y, Mouloudj D, et al. Efficacy and safety of targeted therapies in VEXAS syndrome: retrospective study from the FRENVEX. Ann Rheum Dis. 2024. PMID: 38777378. doi:10.1136/ard-2024-225640

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。